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Division of Genetic and Molecular Toxicology, National Center for Toxicological Research, US FDA, Jefferson, AR, United StatesAcquired resistance to molecularly targeted therapies is a major Various detection techniques for RAS mutations are available, but
obstacle blocking effective treatment of cancer patients. This is par-
ticularly true for therapies that target the epidermal growth factor
receptor (EGFR) [1,2]. Acquired resistance to molecularly targeted
therapies may occur de novo (meaning as a consequence of the se-
lective pressure of treatment), or may be due to outgrowth of
preexisting tumor subpopulations that are resistant to treatment
[3]. Clinical studies have shown that undetected populations of
tumor cells carrying KRAS mutations lead to therapeutic resistance
and relapse in colorectal cancer (CRC) patients [4,5]. Consequently,
the ability to assess the impact of minor mutant subpopulations on
therapeutic resistance has important implications regarding the de-
velopment of effective strategies for personalized cancer treatment.
Detecting and analyzing the major and minor mutant subpopula-
tions of cells carrying speciﬁc oncogene mutations in a patient's
tumor, therefore, are crucial.
The presence of some RASmutations, especially KRAS codon 12 mu-
tations, in CRC patients is associated with poor prognosis and predicts
lack of response to therapies that target the EGFR (e.g.,cetuximab, and
panitumumab) [4]. Therefore, detecting KRAS mutations is important
for CRC patients undergoing anti-EGFR therapy. Mutations in KRAS
occur most frequently on exon 2 (codons 12 and 13) and to a lesser ex-
tent on exon 3 (codon 61). The multicenter RASCAL study provided ev-
idence that there were different prognoses for CRC patients harboring
different KRASmutations in their tumors. KRAS codon 12 mutations, es-
pecially G12V, is associated with poor prognosis, whereas patients with
KRAS codon 13 mutations respond better to the therapies [6]. Accurate
detection of RASmutations that occur at high and low frequency is crit-
ical for identifying the best strategies for intervention. An ideal assay for
detection of RASmutations: 1) should have the ability to determine RAS
mutationswith high levels of speciﬁcity and sensitivity, 2) be able to de-
termine different levels of RASmutations in colorectal tumors quantita-
tively, 3) should also be able to detect minor mutant subpopulations of
RASmutations; and 4) should employ a multiplex approach, in order to
detect several RASmutations from small amount of DNA in a short turn-
around time.DOI of original article: http://dx.doi.org/10.1016/j.ebiom.2015.02.007.
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done mostly by direct sequencing (DS) or real time PCR assays, which
may be expensive and time consuming. In this issue of EBioMedicine,
Dr. Takayuki Yoshino and colleagues report on the utility of the
MEBGENRASKETKIT (RASKET), amultiplex assay using PCR-reverse se-
quence speciﬁc oligonucleotide with xMAP technology. This assay can
detect 48 RAS (KRAS and NRAS) mutations in exons 2, 3 and 4, with a
short turnaround time of 4.5 h for 96 specimens [7]. Moreover, the
RASKET results had high concordance with those obtained using DS
and the TheraScreen KRAS RGQ Polymerase chain reaction kit. The
RASKET can detect mutant fractions of around 1–5% which is similar
to TheraScreen KRAS mutation kit and is higher than DS. There are
other sensitive assays for KRAS detection such as the Allele Speciﬁc
Competitive Blocker Polymerase Chain Reaction (ACB-PCR) that can de-
tect KRASmutations fractions as low as 0.001% (1mutant out of 100,000
wild-type) [8]. The sensitivity of an assaywill impactwhether a colorec-
tal tumor is KRASmutant or wild-type [9]. With ACB-PCR, KRAS codon
12 mutations are detected in 100% of colon tumors and also in some
normal colonic mucosa [8]. The levels of different RAS mutations that
are “pathological” have not yet been rigorously established for CRC pa-
tients [8]. Nevertheless, it has been demonstrated that the KRASmutant
subclones known to cause resistance to anti-EGFR therapy are quite
prevalent and frequently occur at low levels (levels below the detection
limit by DS [8]). There is evidence that a signiﬁcant number of CRC pa-
tients characterized as KRASwild-type fail to respond to EGFR therapy
[9]. This could be due in part to the insensitive techniques that clinicians
use for KRASmutation detection or due to the presence of other unde-
tected mutations in different genes in the RAF–MEK–ERK kinase path-
way. RASKET, similar to DS and the TheraScreen kit, does not provide
quantitation of the detected RASmutations. Therefore, these methodol-
ogies may not be sufﬁcient for establishing whether particular levels of
mutation are associated with clinical response. RASmutations are fre-
quently present as small subpopulations within colon tumors, which
are remarkably heterogeneous and may often be polyclonal in origin
[10]. Therefore, it seems likely that both sensitive and quantitative
methodologies to characterize RAS mutations will be required to ad-
vance personalized treatment of colon cancer.
The RASKET kit has its limitations: it does not measure the RASmu-
tations quantitatively and also there are other more sensitive assays
available tomeasure RASmutations. Nonetheless, the RASKETmultiplex
assay detects exons 2, 3 and 4 KRAS and NRAS mutations from a small
amount of DNA (50–100 ng) that is extracted from formalin ﬁxed paraf-
ﬁn embedded tissues in a short turnaround time of 4.5 h.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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